Literature DB >> 23625284

Granulomas of intestinal tuberculosis and Crohn's disease can be differentiated by CD73 cell surface marker expression: a pilot study.

Rupa Banerjee1, M Balaji, M Sasikala, S Anuradha, G V Rao, D Nageshwar Reddy.   

Abstract

BACKGROUND: Intestinal tuberculosis (ITB) and Crohn's disease are similar granulomatous disorders. Granulomas are present in both and difficult to differentiate on histopathology alone. A recent study demonstrated recruitment of mesenchymal cells (MSCs) at the periphery of granulomas in lymph node tuberculosis which suppressed T cell responses. We hypothesized that granulomas of ITB would also recruit MSCs to evade host immune response. AIM: The purpose of this study was to demonstrate MSC markers in granulomas of ITB and evaluate whether distribution of MSC markers could differentiate between granulomas of Crohn's and ITB.
METHODS: We initially retrospectively enrolled 17 patients with confirmed ITB (8) or Crohn's (9) with granulomas on histopathology. Tissues were evaluated by immunofluorescence for MSC markers CD29, CD90, CD73 and absence of haematopoietic markers CD31, CD34, CD45 and CD14. Double-staining was done to confirm presence of MSCs. Subsequently, 23 postoperative specimens of Crohn's (18) and ITB (5) were analyzed for validation.
RESULTS: Overall, 27 Crohn's and 13 ITB cases were assessed. CD29 and CD90 positive cells were noted around both ITB and Crohn's granulomas. MSC marker CD73 was expressed around the granulomas of ITB alone and was completely absent in the Crohn's. The subsequent assessment of granulomas in postoperative specimens of Crohn's and ITB also showed similar results.
CONCLUSION: Granulomas of ITB and Crohn's disease can be differentiated by CD73 MSC surface marker expression. The differential CD73 expression around ITB granuloma indicates that Mycobacterium tuberculosis evades host immunity by recruiting MSCs with CD73 expression. MSCs with increased CD73 expression could be the future for therapeutic intervention in Crohn's.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625284     DOI: 10.1007/s10620-013-2667-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

1.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Authors:  Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

Review 2.  Role of adenosine in immunomodulation: review of the literature.

Authors:  Kevin McCallion; Denis W Harkin; Keith R Gardiner
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

Review 3.  Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity?

Authors:  Daniel J B Marks
Journal:  Curr Opin Gastroenterol       Date:  2011-07       Impact factor: 3.287

4.  Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease.

Authors:  Rachele Ciccocioppo; Maria Ester Bernardo; Adele Sgarella; Rita Maccario; Maria Antonietta Avanzini; Cristina Ubezio; Antonella Minelli; Costanza Alvisi; Alessandro Vanoli; Fabrizio Calliada; Paolo Dionigi; Cesare Perotti; Franco Locatelli; Gino Roberto Corazza
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 6.  Epidemiology of inflammatory bowel disease in Asia.

Authors:  Ajit Sood; Vandana Midha
Journal:  Indian J Gastroenterol       Date:  2007 Nov-Dec

Review 7.  Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis.

Authors:  D Epstein; G Watermeyer; R Kirsch
Journal:  Aliment Pharmacol Ther       Date:  2007-06-15       Impact factor: 8.171

Review 8.  The dyspeptic macrophage 30 years later: an update in the pathogenesis of Crohn's disease.

Authors:  R Caprilli; G Frieri
Journal:  Dig Liver Dis       Date:  2008-11-20       Impact factor: 4.088

9.  Physiological roles for ecto-5'-nucleotidase (CD73).

Authors:  Sean P Colgan; Holger K Eltzschig; Tobias Eckle; Linda F Thompson
Journal:  Purinergic Signal       Date:  2006-06-01       Impact factor: 3.765

10.  Mesenchymal stem cells.

Authors:  A I Caplan
Journal:  J Orthop Res       Date:  1991-09       Impact factor: 3.494

View more
  8 in total

1.  Mesenchymal stem cells and granulomas in Crohn's disease and intestinal tuberculosis: the way forward.

Authors:  Nayak Suprabha; C Ganesh Pai
Journal:  Dig Dis Sci       Date:  2013-10-26       Impact factor: 3.199

2.  TB or Not TB: Crohn's Disease, Peritoneal Tuberculosis, or Both?

Authors:  Miquell Miller; Kim-Nhien Vu; Allison Zemek; Andrew Shelton; Cindy Kin
Journal:  Dig Dis Sci       Date:  2019-06       Impact factor: 3.199

Review 3.  Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut.

Authors:  Maria Serena Longhi; Lili Feng; Simon C Robson
Journal:  Biochem Pharmacol       Date:  2021-01-15       Impact factor: 5.858

Review 4.  Recent advances in the diagnosis of intestinal tuberculosis.

Authors:  Hasan Maulahela; Marcellus Simadibrata; Erni Juwita Nelwan; Nur Rahadiani; Editha Renesteen; S W T Suwarti; Yunita Windi Anggraini
Journal:  BMC Gastroenterol       Date:  2022-03-01       Impact factor: 3.067

5.  Distinguishing between Crohn's disease, tuberculosis, and lymphoma: still in murky waters.

Authors:  Majid A Almadi
Journal:  Saudi J Gastroenterol       Date:  2014 Jul-Aug       Impact factor: 2.485

Review 6.  Inflammatory bowel disease in India - Past, present and future.

Authors:  Gautam Ray
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

Review 7.  Differentiating Crohn's disease from intestinal tuberculosis.

Authors:  Saurabh Kedia; Prasenjit Das; Kumble Seetharama Madhusudhan; Siddhartha Dattagupta; Raju Sharma; Peush Sahni; Govind Makharia; Vineet Ahuja
Journal:  World J Gastroenterol       Date:  2019-01-28       Impact factor: 5.742

Review 8.  Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.

Authors:  Xueying Zhang; Qi Xie; Ziyu Ye; Yanyun Li; Zhengping Che; Mingyuan Huang; Jincheng Zeng
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.